Tonsil-derived mesenchymal stem cell-embedded in situ crosslinkable gelatin hydrogel therapy recovers postmenopausal osteoporosis through bone regeneration.
Gyungah KimYoon Shin ParkYunki LeeYoon Mi JinDa Hyeon ChoiKyung-Ha RyuYoon Jeong ParkKi Dong ParkInho JoPublished in: PloS one (2018)
We investigated therapeutic potential of human tonsil-derived mesenchymal stem cells (TMSC) subcutaneously delivered to ovariectomized (OVX) mice for developing more safe and effective therapy for osteoporosis. TMSC were isolated from tonsil tissues of children undergoing tonsillectomy, and TMSC-embedded in situ crosslinkable gelatin-hydroxyphenyl propionic acid hydrogel (TMSC-GHH) or TMSC alone were delivered subcutaneously to the dorsa of OVX mice. After 3 months, three-dimensionally reconstructed micro-computed tomographic images revealed better recovery of the femoral heads in OVX mice treated with TMSC-GHH. Serum osteocalcin and alkaline phosphatase were also recovered, indicating bone formation only in TMSC-GHH-treated mice, and absence in hypercalcemia or other severe macroscopic deformities showed biocompatibility of TMSC-GHH. Additionally, visceral fat reduction effects by TMSC-GHH further supported their therapeutic potential. TMSC provided therapeutic benefits toward osteoporosis only when embedded in GHH, and showed potential as a supplement or alternative to current therapies.
Keyphrases
- bone regeneration
- high fat diet induced
- bone mineral density
- postmenopausal women
- hyaluronic acid
- tissue engineering
- mesenchymal stem cells
- drug delivery
- endothelial cells
- insulin resistance
- deep learning
- stem cells
- bone marrow
- type diabetes
- metabolic syndrome
- wild type
- machine learning
- body composition
- early onset
- skeletal muscle
- umbilical cord
- pluripotent stem cells